Sublingual Versus Endovenous Fentanyl for the Prehospital Analgesia in Patients With Limb Trauma on the Slope

Sponsor
Azienda Sanitaria dell'Alto Adige (Other)
Overall Status
Completed
CT.gov ID
NCT03080350
Collaborator
Institute of Mountain Emergency Medicine (Other)
108
1
2
13.9
7.8

Study Details

Study Description

Brief Summary

The purpose of this study is to determine the non-inferiority of the efficacy for prehospital analgesia of sublingual administered fentanyl versus endovenous administered fentanyl for patients with limb trauma on the slope

Condition or Disease Intervention/Treatment Phase
  • Drug: Fentanyl sublingual
  • Drug: Fentanyl ev
  • Drug: Placebo sublingual
  • Drug: Placebo ev
Phase 4

Detailed Description

Fentanyl endovenous (ev) is an excellent analgesic drug for pain relief in acute traumatic pain. Fentanyl sublingual (Abstral ®) is an excellent analgesic drug in the breakthrough cancer pain relief in oncologic patients.

The immediate (less than 10 minutes) effect and the ease of administration of sublingual fentanyl is a feasible drug administration for immediate analgesia in remote areas such as mountain rescue missions eg. the slope.

Patients will be recruited according to a randomized list to fentanyl ev or fentanyl sublingual versus placebo oral or placebo ev.

Safety issues like control of vital signs will be warranted.

Study Design

Study Type:
Interventional
Actual Enrollment :
108 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Care Provider, Investigator)
Primary Purpose:
Treatment
Official Title:
Sublingual Versus Endovenous Fentanyl for the Prehospital Analgesia in Patients With Limb Trauma on the Slope - a Double-blind Randomized Prospective Study
Actual Study Start Date :
Jan 1, 2017
Actual Primary Completion Date :
Mar 1, 2018
Actual Study Completion Date :
Mar 1, 2018

Arms and Interventions

Arm Intervention/Treatment
Experimental: Fentanyl sublingual + Placebo ev

Fentanyl 100 µg sublingual in acute sever pain + NaCl 0,9% endovenous to mimic fentanyl ev

Drug: Fentanyl sublingual
Fentanyl sublingual
Other Names:
  • Abstral
  • Drug: Placebo ev
    Placebo - NaCL 0,9% ev

    Active Comparator: Fentanyl ev + Placebo sublingual

    Fentanyl ev in acute sever pain + Sugar pill manufactured to mimic fentanyl sublingual

    Drug: Fentanyl ev
    Fentanyl ev

    Drug: Placebo sublingual
    Placebo sublingual

    Outcome Measures

    Primary Outcome Measures

    1. Pain - Relief [1 hour]

      Pain - Relief of 2 points on a 11 items pain scale (0 = non pain; 10 = unbearable pain)

    Secondary Outcome Measures

    1. Practicability / handling of the two dosage forms of fentanyl in emergencies [1 hour]

      Practicability / handling

    2. Patient comfort [1 hour]

      5 items Labert Scale

    3. Adverse drug effects [1 hour]

      such as pruritus, nausea, dizziness

    4. SpO2 (%) [1 hour]

      SpO2 < 92%

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Trauma on the limbs with a pain score of 4 or more on the slope

    • ASA I - II

    Exclusion Criteria:
    • children (< 18 years)

    • cognitive impairment: brain injury, intoxication, analgesia

    • weight under 50 kg and more than 100 kg

    • other injuries like chest trauma with respiratory insufficiency, suspect liver or spleen injury, amputation;

    • chronic analgesic use or misuse

    • allergy

    • fear of needles

    • pregnancy

    • speech difficulties

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Skiresort - Kronplatz Bruneck Italy 39031

    Sponsors and Collaborators

    • Azienda Sanitaria dell'Alto Adige
    • Institute of Mountain Emergency Medicine

    Investigators

    • Principal Investigator: Rosmarie Oberhammer, MD, Südtiroler Sanitätsbetrieb - Bruneck Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Elisabeth Gruber, MD, Azienda Sanitaria dell'Alto Adige
    ClinicalTrials.gov Identifier:
    NCT03080350
    Other Study ID Numbers:
    • SABES Pain 2
    First Posted:
    Mar 15, 2017
    Last Update Posted:
    Mar 4, 2020
    Last Verified:
    Mar 1, 2020
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Elisabeth Gruber, MD, Azienda Sanitaria dell'Alto Adige
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 4, 2020